Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience
Luca Diamanti(Fondazione Istituto Neurologico Nazionale Casimiro Mondino), Enrico Marchioni(Fondazione Istituto Neurologico Nazionale Casimiro Mondino), Anna Pichiecchio(University of Pavia), Matteo Gastaldi(Fondazione Istituto Neurologico Nazionale Casimiro Mondino), Veronica Villani(Istituti di Ricovero e Cura a Carattere Scientifico), Edvina Galiè(Istituti di Ricovero e Cura a Carattere Scientifico), Bruno Giometto(Provincia Autonoma di Trento), Mariarosaria Valente(University of Udine), Alberto Vogrig(University of Udine), Francesco Bruno(Piedmont Reference Center for Epidemiology and Cancer Prevention), Valentina Poretto(Ospedale Santa Chiara), Eugenia Rota(Ospedale San Giacomo Apostolo), Alberto Pïcca(Centre National de la Recherche Scientifique), Roberta Rudà, Carolina Cimminiello(Fondazione IRCCS Istituto Nazionale dei Tumori), Enrico Alfonsi(Foundation Center), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Marco Zoccarato, Paola Bini(Fondazione Istituto Neurologico Nazionale Casimiro Mondino)
Cited by 36
Related Papers
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780
Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes
|Neurology Neuroimmunology & Neuroinflammation|2021|702
Interleukin-12: Biological Properties and Clinical Application
|Clinical Cancer Research|2007|606